| Primary |
| Ovarian Cancer |
28.1% |
| Product Used For Unknown Indication |
15.7% |
| Ovarian Cancer Recurrent |
11.9% |
| Premedication |
6.5% |
| Hypertension |
5.4% |
| Cardiovascular Disorder |
4.3% |
| Sarcoma |
4.3% |
| Pain In Extremity |
3.2% |
| Depression |
2.7% |
| Drug Use For Unknown Indication |
2.2% |
| Anxiety |
1.6% |
| Blood Calcium Decreased |
1.6% |
| Cardiac Failure Chronic |
1.6% |
| Chemotherapy |
1.6% |
| Diabetes Mellitus |
1.6% |
| Hypercholesterolaemia |
1.6% |
| Hypothyroidism |
1.6% |
| Oedema Due To Cardiac Disease |
1.6% |
| Platelet Aggregation Inhibition |
1.6% |
| Liposarcoma |
1.1% |
|
| Bone Marrow Failure |
13.3% |
| Vomiting |
13.3% |
| Renal Failure Acute |
11.1% |
| Thrombocytopenia |
8.9% |
| Atrial Fibrillation |
6.7% |
| Rhabdomyolysis |
6.7% |
| Cardiac Failure |
4.4% |
| Haematotoxicity |
4.4% |
| Hepatic Function Abnormal |
4.4% |
| Urinary Retention |
4.4% |
| Blood Creatine Increased |
2.2% |
| Blood Creatinine Increased |
2.2% |
| Cognitive Disorder |
2.2% |
| Colitis |
2.2% |
| Diarrhoea |
2.2% |
| Drug Interaction |
2.2% |
| Dyspnoea |
2.2% |
| Extravasation |
2.2% |
| Febrile Neutropenia |
2.2% |
| Hepatic Enzyme Increased |
2.2% |
|
| Secondary |
| Hypertension |
9.4% |
| Ovarian Cancer |
8.8% |
| Premedication |
8.3% |
| Product Used For Unknown Indication |
8.0% |
| Ovarian Cancer Recurrent |
7.1% |
| Vomiting |
6.8% |
| Nausea |
5.8% |
| Dyspepsia |
5.6% |
| Sarcoma |
5.3% |
| Arthralgia |
4.6% |
| Ovarian Neoplasm |
4.1% |
| Prophylactic Chemotherapy |
4.1% |
| Chemotherapy |
3.6% |
| Liposarcoma |
3.2% |
| Osteoporosis |
3.1% |
| Diabetes Mellitus |
2.6% |
| Pain |
2.6% |
| Atrial Fibrillation |
2.4% |
| Drug Use For Unknown Indication |
2.4% |
| Pain In Extremity |
2.4% |
|
| Sepsis |
13.8% |
| Myalgia |
11.9% |
| Bone Marrow Failure |
8.3% |
| Cardiac Failure |
7.3% |
| Cytolytic Hepatitis |
7.3% |
| Upper Gastrointestinal Haemorrhage |
4.6% |
| Vomiting |
4.6% |
| Confusional State |
3.7% |
| Idiopathic Thrombocytopenic Purpura |
3.7% |
| Pericarditis |
3.7% |
| Renal Failure Acute |
3.7% |
| Thrombocytopenia |
3.7% |
| Urinary Retention |
3.7% |
| Ventricular Hypokinesia |
3.7% |
| Blood Creatine Phosphokinase Increased |
2.8% |
| Death |
2.8% |
| Gamma-glutamyltransferase Increased |
2.8% |
| Hyperkalaemia |
2.8% |
| Hypotension |
2.8% |
| Neutropenia |
2.8% |
|
| Concomitant |
| Sarcoma |
20.5% |
| Condition Aggravated |
15.4% |
| Liposarcoma |
15.4% |
| Product Used For Unknown Indication |
10.3% |
| Prophylaxis |
10.3% |
| Hypertension |
7.7% |
| Deep Vein Thrombosis |
5.1% |
| Metastases To Bone |
5.1% |
| Depression |
2.6% |
| Neoplasm Malignant |
2.6% |
| Thrombosis |
2.6% |
| Uterine Leiomyosarcoma |
2.6% |
|
| Cardiac Failure |
23.1% |
| Vomiting |
23.1% |
| Off Label Use |
15.4% |
| Urinary Tract Infection |
15.4% |
| Aphasia |
7.7% |
| Disease Progression |
7.7% |
| Hypertensive Crisis |
7.7% |
|
| Interacting |
| Product Used For Unknown Indication |
28.0% |
| Cardiovascular Disorder |
15.5% |
| Hiv Test Positive |
13.0% |
| Drug Use For Unknown Indication |
8.7% |
| Chemotherapy |
6.8% |
| Hiv Infection |
5.8% |
| Hypertension |
5.8% |
| Sarcoma Metastatic |
4.8% |
| Liposarcoma |
3.9% |
| Premedication |
1.9% |
| Sarcoma Uterus |
1.9% |
| Metastases To Lung |
1.4% |
| Uterine Leiomyosarcoma |
1.4% |
| Ill-defined Disorder |
1.0% |
|
| Pyrexia |
24.0% |
| Drug Interaction |
16.0% |
| Myalgia |
16.0% |
| Ascites |
8.0% |
| Lymphangiosis Carcinomatosa |
8.0% |
| Chest Pain |
4.0% |
| Cough |
4.0% |
| General Physical Health Deterioration |
4.0% |
| Hepatic Enzyme Increased |
4.0% |
| Liver Function Test Abnormal |
4.0% |
| Pancytopenia |
4.0% |
| Rhabdomyolysis |
4.0% |
|
